| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 37 | 2023 | 2159 | 2.940 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 18 | 2018 | 959 | 1.850 |
Why?
|
| Pacemaker, Artificial | 4 | 2020 | 106 | 1.830 |
Why?
|
| Hospitals, Veterans | 7 | 2020 | 244 | 1.780 |
Why?
|
| Skilled Nursing Facilities | 3 | 2020 | 121 | 1.720 |
Why?
|
| United States Department of Veterans Affairs | 13 | 2021 | 561 | 1.570 |
Why?
|
| Percutaneous Coronary Intervention | 11 | 2021 | 445 | 1.550 |
Why?
|
| Prosthesis-Related Infections | 4 | 2020 | 70 | 1.450 |
Why?
|
| Transitional Care | 2 | 2020 | 34 | 1.290 |
Why?
|
| Multiple Pulmonary Nodules | 3 | 2023 | 22 | 1.220 |
Why?
|
| Veterans | 12 | 2020 | 1248 | 1.170 |
Why?
|
| Subacute Care | 2 | 2019 | 71 | 1.160 |
Why?
|
| Myocardial Infarction | 9 | 2018 | 932 | 1.120 |
Why?
|
| Aged | 69 | 2024 | 18969 | 1.060 |
Why?
|
| Patient Discharge | 5 | 2020 | 770 | 1.050 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2023 | 19 | 1.030 |
Why?
|
| Defibrillators, Implantable | 2 | 2020 | 287 | 0.960 |
Why?
|
| Coronary Artery Disease | 8 | 2021 | 611 | 0.920 |
Why?
|
| Middle Aged | 74 | 2021 | 26605 | 0.910 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 7 | 2013 | 224 | 0.910 |
Why?
|
| Male | 103 | 2024 | 55396 | 0.880 |
Why?
|
| Pyrazoles | 5 | 2013 | 361 | 0.870 |
Why?
|
| Female | 105 | 2024 | 59324 | 0.850 |
Why?
|
| United States | 33 | 2021 | 12137 | 0.810 |
Why?
|
| Pyridines | 4 | 2013 | 419 | 0.790 |
Why?
|
| Cardiac Catheterization | 6 | 2020 | 545 | 0.760 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2019 | 95 | 0.730 |
Why?
|
| Quinazolines | 6 | 2008 | 240 | 0.730 |
Why?
|
| Retrospective Studies | 33 | 2021 | 12521 | 0.720 |
Why?
|
| Humans | 132 | 2024 | 114045 | 0.720 |
Why?
|
| Heart Failure | 5 | 2024 | 1958 | 0.710 |
Why?
|
| Antineoplastic Agents | 11 | 2013 | 1875 | 0.700 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2019 | 1175 | 0.670 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2018 | 577 | 0.670 |
Why?
|
| Risk Factors | 31 | 2023 | 8614 | 0.670 |
Why?
|
| Surgical Wound Infection | 2 | 2020 | 246 | 0.620 |
Why?
|
| Myocardial Ischemia | 2 | 2019 | 239 | 0.620 |
Why?
|
| Survival Analysis | 9 | 2020 | 1206 | 0.610 |
Why?
|
| Adenocarcinoma | 7 | 2017 | 787 | 0.610 |
Why?
|
| Ventricular Function, Right | 1 | 2020 | 256 | 0.610 |
Why?
|
| Mucin 5AC | 1 | 2018 | 48 | 0.600 |
Why?
|
| Stroke Volume | 2 | 2020 | 513 | 0.600 |
Why?
|
| Electronic Health Records | 3 | 2020 | 799 | 0.590 |
Why?
|
| Clostridium Infections | 1 | 2018 | 54 | 0.590 |
Why?
|
| ErbB Receptors | 7 | 2018 | 554 | 0.590 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2018 | 784 | 0.590 |
Why?
|
| Vancomycin | 1 | 2018 | 75 | 0.580 |
Why?
|
| Palliative Care | 2 | 2024 | 641 | 0.570 |
Why?
|
| Patient Readmission | 6 | 2020 | 607 | 0.560 |
Why?
|
| Population Surveillance | 1 | 2020 | 385 | 0.560 |
Why?
|
| Biomarkers, Tumor | 9 | 2018 | 1032 | 0.550 |
Why?
|
| Carcinogenesis | 1 | 2018 | 175 | 0.550 |
Why?
|
| Quality Assurance, Health Care | 2 | 2017 | 308 | 0.540 |
Why?
|
| Nevus, Pigmented | 2 | 2014 | 34 | 0.540 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2024 | 907 | 0.530 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 395 | 0.530 |
Why?
|
| Follow-Up Studies | 18 | 2022 | 4392 | 0.510 |
Why?
|
| Risk Assessment | 8 | 2021 | 2958 | 0.510 |
Why?
|
| Melanosis | 2 | 2014 | 13 | 0.500 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 637 | 0.500 |
Why?
|
| Medication Errors | 1 | 2016 | 88 | 0.500 |
Why?
|
| Aged, 80 and over | 15 | 2020 | 6306 | 0.500 |
Why?
|
| Heart Ventricles | 1 | 2020 | 723 | 0.490 |
Why?
|
| Time Factors | 14 | 2020 | 6077 | 0.490 |
Why?
|
| Surgical Procedures, Operative | 1 | 2017 | 206 | 0.490 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2024 | 495 | 0.490 |
Why?
|
| Medicare | 5 | 2021 | 661 | 0.490 |
Why?
|
| Cohort Studies | 20 | 2023 | 4883 | 0.490 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2014 | 8 | 0.480 |
Why?
|
| Albinism, Oculocutaneous | 1 | 2014 | 6 | 0.480 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 150 | 0.470 |
Why?
|
| Specialization | 1 | 2015 | 112 | 0.460 |
Why?
|
| Algorithms | 3 | 2020 | 1469 | 0.460 |
Why?
|
| Antimicrobial Stewardship | 1 | 2016 | 92 | 0.460 |
Why?
|
| Glutamates | 2 | 2013 | 57 | 0.450 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 1204 | 0.450 |
Why?
|
| Guanine | 2 | 2013 | 76 | 0.450 |
Why?
|
| Anti-Infective Agents | 1 | 2016 | 219 | 0.440 |
Why?
|
| Telemedicine | 2 | 2024 | 662 | 0.440 |
Why?
|
| End Stage Liver Disease | 1 | 2014 | 61 | 0.430 |
Why?
|
| Autoimmunity | 6 | 2019 | 812 | 0.430 |
Why?
|
| Incidence | 13 | 2018 | 2314 | 0.430 |
Why?
|
| Exercise Test | 2 | 2015 | 547 | 0.420 |
Why?
|
| Sputum | 3 | 2012 | 286 | 0.420 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 1471 | 0.420 |
Why?
|
| Early Detection of Cancer | 3 | 2021 | 305 | 0.410 |
Why?
|
| Prognosis | 11 | 2020 | 3315 | 0.410 |
Why?
|
| Parkinson Disease | 3 | 2012 | 345 | 0.410 |
Why?
|
| Databases, Factual | 9 | 2020 | 1125 | 0.400 |
Why?
|
| Physicians, Primary Care | 1 | 2015 | 222 | 0.400 |
Why?
|
| Reoperation | 1 | 2014 | 513 | 0.400 |
Why?
|
| Tissue Donors | 1 | 2014 | 314 | 0.400 |
Why?
|
| Survivors | 1 | 2015 | 412 | 0.390 |
Why?
|
| Mortality | 6 | 2020 | 283 | 0.390 |
Why?
|
| Quality of Life | 4 | 2024 | 2343 | 0.390 |
Why?
|
| Glomerular Filtration Rate | 2 | 2020 | 605 | 0.390 |
Why?
|
| Hepatitis C | 1 | 2014 | 218 | 0.390 |
Why?
|
| Treatment Outcome | 19 | 2021 | 9049 | 0.370 |
Why?
|
| Lung | 7 | 2020 | 3521 | 0.370 |
Why?
|
| In Situ Hybridization, Fluorescence | 8 | 2016 | 308 | 0.370 |
Why?
|
| Hypertension, Pulmonary | 5 | 2020 | 1736 | 0.360 |
Why?
|
| Islets of Langerhans | 5 | 2019 | 728 | 0.360 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 949 | 0.350 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2017 | 1356 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2020 | 813 | 0.340 |
Why?
|
| Physical Therapy Modalities | 3 | 2012 | 265 | 0.330 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 1078 | 0.330 |
Why?
|
| Glutens | 2 | 2019 | 56 | 0.320 |
Why?
|
| Viremia | 1 | 2009 | 122 | 0.320 |
Why?
|
| Breast Neoplasms | 5 | 2015 | 1846 | 0.310 |
Why?
|
| Gene Rearrangement | 6 | 2017 | 135 | 0.310 |
Why?
|
| Skin Neoplasms | 6 | 2018 | 754 | 0.310 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2018 | 607 | 0.310 |
Why?
|
| Adaptive Immunity | 1 | 2009 | 154 | 0.310 |
Why?
|
| Veterans Health | 3 | 2019 | 166 | 0.310 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 86 | 0.300 |
Why?
|
| Severity of Illness Index | 6 | 2018 | 2537 | 0.300 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 1145 | 0.290 |
Why?
|
| Liver Transplantation | 1 | 2014 | 695 | 0.290 |
Why?
|
| Stroke | 5 | 2018 | 1019 | 0.290 |
Why?
|
| Cytomegalovirus Infections | 1 | 2009 | 180 | 0.290 |
Why?
|
| Medicaid | 3 | 2021 | 404 | 0.290 |
Why?
|
| Carcinoma, Small Cell | 1 | 2008 | 158 | 0.280 |
Why?
|
| Adult | 35 | 2024 | 30375 | 0.280 |
Why?
|
| Patient Care Team | 2 | 2024 | 517 | 0.280 |
Why?
|
| Postoperative Complications | 3 | 2020 | 2122 | 0.280 |
Why?
|
| Primary Health Care | 1 | 2016 | 1502 | 0.280 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2009 | 519 | 0.260 |
Why?
|
| Hospitalization | 5 | 2019 | 1762 | 0.260 |
Why?
|
| Sunburn | 2 | 2018 | 25 | 0.260 |
Why?
|
| Accidental Falls | 2 | 2018 | 151 | 0.260 |
Why?
|
| Disease Progression | 12 | 2019 | 2371 | 0.260 |
Why?
|
| Quality Improvement | 3 | 2018 | 944 | 0.260 |
Why?
|
| Diabetes Mellitus, Type 1 | 9 | 2019 | 3254 | 0.250 |
Why?
|
| Secondary Prevention | 2 | 2019 | 221 | 0.250 |
Why?
|
| Erythropoietin | 1 | 2006 | 72 | 0.250 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 4 | 2018 | 228 | 0.250 |
Why?
|
| Ultraviolet Rays | 3 | 2018 | 363 | 0.250 |
Why?
|
| Program Evaluation | 3 | 2018 | 820 | 0.240 |
Why?
|
| Celiac Disease | 2 | 2019 | 264 | 0.240 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2020 | 76 | 0.240 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2020 | 486 | 0.240 |
Why?
|
| Mutation | 7 | 2018 | 3338 | 0.240 |
Why?
|
| Retinopathy of Prematurity | 1 | 2006 | 111 | 0.230 |
Why?
|
| Lung Diseases | 3 | 2024 | 690 | 0.230 |
Why?
|
| Immunity, Innate | 1 | 2009 | 720 | 0.230 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2020 | 180 | 0.230 |
Why?
|
| Lower Extremity | 2 | 2018 | 334 | 0.230 |
Why?
|
| Andropause | 2 | 2014 | 6 | 0.230 |
Why?
|
| Oncogenes | 2 | 2016 | 104 | 0.220 |
Why?
|
| Cell Proliferation | 4 | 2018 | 2173 | 0.220 |
Why?
|
| Acute Coronary Syndrome | 2 | 2018 | 254 | 0.210 |
Why?
|
| Nevus | 3 | 2018 | 26 | 0.200 |
Why?
|
| Precancerous Conditions | 3 | 2020 | 155 | 0.190 |
Why?
|
| Neoplasms, Experimental | 2 | 2018 | 149 | 0.190 |
Why?
|
| Erythrocyte Membrane | 2 | 2015 | 50 | 0.190 |
Why?
|
| Gene Dosage | 2 | 2016 | 129 | 0.190 |
Why?
|
| Diet | 5 | 2019 | 1080 | 0.190 |
Why?
|
| Prospective Studies | 7 | 2023 | 6195 | 0.190 |
Why?
|
| Medication Adherence | 3 | 2014 | 531 | 0.180 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2015 | 122 | 0.180 |
Why?
|
| Chi-Square Distribution | 3 | 2018 | 492 | 0.180 |
Why?
|
| Smoking | 4 | 2019 | 1382 | 0.180 |
Why?
|
| Testosterone | 2 | 2014 | 341 | 0.180 |
Why?
|
| ras Proteins | 3 | 2012 | 138 | 0.180 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2020 | 39 | 0.180 |
Why?
|
| Hospitals, Community | 1 | 2020 | 45 | 0.170 |
Why?
|
| Melanoma | 4 | 2012 | 620 | 0.170 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 72 | 0.170 |
Why?
|
| Carcinoma | 1 | 2021 | 198 | 0.170 |
Why?
|
| Cadherins | 3 | 2006 | 175 | 0.170 |
Why?
|
| Longitudinal Studies | 10 | 2019 | 2384 | 0.170 |
Why?
|
| Autoantibodies | 4 | 2019 | 1347 | 0.170 |
Why?
|
| Datasets as Topic | 1 | 2020 | 98 | 0.170 |
Why?
|
| Episode of Care | 1 | 2019 | 5 | 0.160 |
Why?
|
| Elective Surgical Procedures | 1 | 2020 | 150 | 0.160 |
Why?
|
| Patient Identification Systems | 1 | 2019 | 16 | 0.160 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 98 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2020 | 2087 | 0.160 |
Why?
|
| Fluid Therapy | 1 | 2020 | 121 | 0.160 |
Why?
|
| Survival Rate | 5 | 2017 | 1638 | 0.160 |
Why?
|
| Critical Pathways | 1 | 2020 | 76 | 0.160 |
Why?
|
| Fee-for-Service Plans | 1 | 2019 | 83 | 0.160 |
Why?
|
| Vascular Resistance | 1 | 2020 | 340 | 0.160 |
Why?
|
| Activities of Daily Living | 2 | 2012 | 348 | 0.160 |
Why?
|
| Perioperative Care | 1 | 2020 | 126 | 0.160 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 1815 | 0.160 |
Why?
|
| Oncogene Proteins | 1 | 2018 | 53 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 1381 | 0.150 |
Why?
|
| Cardiovascular Agents | 1 | 2019 | 125 | 0.150 |
Why?
|
| Retirement | 1 | 2018 | 25 | 0.150 |
Why?
|
| Brain Neoplasms | 3 | 2015 | 966 | 0.150 |
Why?
|
| Dietary Proteins | 1 | 2019 | 121 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 2272 | 0.150 |
Why?
|
| Genotype | 4 | 2017 | 1757 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 67 | 0.150 |
Why?
|
| Histamine H2 Antagonists | 1 | 2018 | 26 | 0.150 |
Why?
|
| Coronary Artery Bypass | 1 | 2019 | 196 | 0.150 |
Why?
|
| Manufacturing Industry | 1 | 2017 | 4 | 0.150 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 237 | 0.150 |
Why?
|
| MicroRNAs | 2 | 2015 | 600 | 0.150 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2018 | 75 | 0.150 |
Why?
|
| Drug Users | 1 | 2018 | 41 | 0.150 |
Why?
|
| Accidents, Occupational | 1 | 2017 | 14 | 0.150 |
Why?
|
| Health Care Sector | 1 | 2017 | 24 | 0.150 |
Why?
|
| Validation Studies as Topic | 1 | 2017 | 23 | 0.150 |
Why?
|
| Homeodomain Proteins | 4 | 2009 | 465 | 0.150 |
Why?
|
| Comorbidity | 3 | 2018 | 1447 | 0.150 |
Why?
|
| Reminder Systems | 1 | 2019 | 159 | 0.150 |
Why?
|
| Thromboembolism | 1 | 2018 | 92 | 0.140 |
Why?
|
| Transportation | 1 | 2017 | 44 | 0.140 |
Why?
|
| Echocardiography | 1 | 2020 | 569 | 0.140 |
Why?
|
| Mice, Transgenic | 3 | 2018 | 1947 | 0.140 |
Why?
|
| Contrast Media | 1 | 2020 | 347 | 0.140 |
Why?
|
| Behavior, Addictive | 1 | 2018 | 81 | 0.140 |
Why?
|
| Atherectomy, Coronary | 1 | 2017 | 11 | 0.140 |
Why?
|
| Patient Transfer | 1 | 2019 | 142 | 0.140 |
Why?
|
| Neoplasm Staging | 4 | 2017 | 1162 | 0.140 |
Why?
|
| Coronary Vessels | 1 | 2019 | 234 | 0.140 |
Why?
|
| Cardiac Output | 1 | 2017 | 143 | 0.140 |
Why?
|
| Occupational Injuries | 1 | 2017 | 46 | 0.140 |
Why?
|
| Odds Ratio | 2 | 2019 | 951 | 0.140 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 108 | 0.140 |
Why?
|
| Colorado | 11 | 2019 | 4090 | 0.140 |
Why?
|
| Beryllium | 1 | 2018 | 146 | 0.140 |
Why?
|
| Chromosome Aberrations | 1 | 2017 | 134 | 0.140 |
Why?
|
| Home Care Services | 1 | 2019 | 219 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2020 | 595 | 0.130 |
Why?
|
| Pemetrexed | 2 | 2013 | 27 | 0.130 |
Why?
|
| Eating | 1 | 2019 | 344 | 0.130 |
Why?
|
| Child | 16 | 2019 | 18401 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2018 | 327 | 0.130 |
Why?
|
| Contraindications | 1 | 2016 | 84 | 0.130 |
Why?
|
| HLA-DQ Antigens | 1 | 2017 | 174 | 0.130 |
Why?
|
| Drug Labeling | 1 | 2016 | 42 | 0.130 |
Why?
|
| Advance Care Planning | 1 | 2019 | 195 | 0.130 |
Why?
|
| Drug Utilization Review | 1 | 2016 | 56 | 0.130 |
Why?
|
| Berylliosis | 1 | 2018 | 177 | 0.130 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 231 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2006 | 181 | 0.130 |
Why?
|
| Bronchi | 2 | 2018 | 223 | 0.130 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2016 | 69 | 0.130 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2016 | 97 | 0.130 |
Why?
|
| HLA-DR Antigens | 1 | 2017 | 219 | 0.130 |
Why?
|
| Data Interpretation, Statistical | 1 | 2017 | 318 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2016 | 67 | 0.130 |
Why?
|
| Vascular Calcification | 1 | 2017 | 106 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2019 | 524 | 0.130 |
Why?
|
| Logistic Models | 3 | 2016 | 1829 | 0.130 |
Why?
|
| Age Factors | 4 | 2018 | 2885 | 0.130 |
Why?
|
| Research Report | 1 | 2016 | 75 | 0.120 |
Why?
|
| Guideline Adherence | 2 | 2019 | 489 | 0.120 |
Why?
|
| Triage | 1 | 2017 | 197 | 0.120 |
Why?
|
| Neoplasm Metastasis | 6 | 2018 | 521 | 0.120 |
Why?
|
| Device Removal | 1 | 2016 | 123 | 0.120 |
Why?
|
| Wounds and Injuries | 3 | 2018 | 674 | 0.120 |
Why?
|
| Taxoids | 3 | 2005 | 93 | 0.120 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 618 | 0.120 |
Why?
|
| Hemorrhage | 2 | 2016 | 600 | 0.120 |
Why?
|
| Biomarkers | 3 | 2022 | 3397 | 0.120 |
Why?
|
| Oligodendroglioma | 1 | 2014 | 15 | 0.120 |
Why?
|
| Health Personnel | 1 | 2020 | 569 | 0.120 |
Why?
|
| Indians, North American | 3 | 2009 | 564 | 0.120 |
Why?
|
| Sex Characteristics | 2 | 2017 | 636 | 0.120 |
Why?
|
| Endovascular Procedures | 1 | 2018 | 267 | 0.120 |
Why?
|
| Gene Expression Profiling | 5 | 2008 | 1518 | 0.120 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2015 | 87 | 0.110 |
Why?
|
| beta-Alanine | 1 | 2014 | 17 | 0.110 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 1422 | 0.110 |
Why?
|
| Mice | 8 | 2018 | 14843 | 0.110 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 2764 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 1168 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 182 | 0.110 |
Why?
|
| Antithrombins | 1 | 2014 | 49 | 0.110 |
Why?
|
| Vascular Surgical Procedures | 1 | 2016 | 260 | 0.110 |
Why?
|
| Neuropilin-2 | 1 | 2013 | 3 | 0.110 |
Why?
|
| Astrocytoma | 1 | 2014 | 106 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 850 | 0.110 |
Why?
|
| Stem Cells | 1 | 2018 | 541 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 2017 | 381 | 0.110 |
Why?
|
| Sulindac | 2 | 2004 | 17 | 0.110 |
Why?
|
| Weight Loss | 2 | 2020 | 642 | 0.110 |
Why?
|
| Cause of Death | 1 | 2015 | 362 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2019 | 1577 | 0.110 |
Why?
|
| Medical Oncology | 1 | 2015 | 229 | 0.110 |
Why?
|
| Cardiotonic Agents | 1 | 2014 | 121 | 0.110 |
Why?
|
| Coronary Angiography | 4 | 2020 | 308 | 0.110 |
Why?
|
| Sex Factors | 3 | 2014 | 1706 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 4 | 2013 | 845 | 0.110 |
Why?
|
| Patient Safety | 1 | 2016 | 273 | 0.110 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2020 | 684 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2014 | 137 | 0.110 |
Why?
|
| Flow Cytometry | 2 | 2006 | 1075 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 3 | 2015 | 280 | 0.100 |
Why?
|
| Child, Preschool | 10 | 2019 | 9114 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 252 | 0.100 |
Why?
|
| Waiting Lists | 1 | 2014 | 206 | 0.100 |
Why?
|
| Mice, Nude | 3 | 2013 | 628 | 0.100 |
Why?
|
| Sunscreening Agents | 1 | 2012 | 17 | 0.100 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 153 | 0.100 |
Why?
|
| Iloprost | 1 | 2012 | 46 | 0.100 |
Why?
|
| Patient Selection | 1 | 2016 | 629 | 0.100 |
Why?
|
| Blood Glucose | 4 | 2020 | 1827 | 0.100 |
Why?
|
| DNA, Neoplasm | 3 | 2011 | 155 | 0.100 |
Why?
|
| Infant | 8 | 2019 | 7943 | 0.100 |
Why?
|
| Biopsy | 4 | 2018 | 1024 | 0.100 |
Why?
|
| Skin Aging | 1 | 2012 | 19 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 167 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2013 | 337 | 0.100 |
Why?
|
| Cell Line, Tumor | 5 | 2013 | 2700 | 0.100 |
Why?
|
| Weight Reduction Programs | 1 | 2013 | 94 | 0.100 |
Why?
|
| Length of Stay | 1 | 2016 | 957 | 0.100 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2012 | 52 | 0.100 |
Why?
|
| Case-Control Studies | 5 | 2021 | 3003 | 0.100 |
Why?
|
| Photography | 1 | 2012 | 88 | 0.090 |
Why?
|
| Sunlight | 1 | 2012 | 58 | 0.090 |
Why?
|
| Calcifediol | 1 | 2011 | 29 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1791 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2015 | 926 | 0.090 |
Why?
|
| Carcinoma, Large Cell | 1 | 2011 | 14 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2016 | 642 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2019 | 2090 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2014 | 511 | 0.090 |
Why?
|
| Phenotype | 3 | 2014 | 2784 | 0.090 |
Why?
|
| Peptides | 1 | 2016 | 847 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 3 | 2011 | 990 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2007 | 1836 | 0.090 |
Why?
|
| Obesity | 3 | 2020 | 2505 | 0.090 |
Why?
|
| Principal Component Analysis | 1 | 2010 | 177 | 0.090 |
Why?
|
| Transplantation, Heterologous | 2 | 2009 | 180 | 0.090 |
Why?
|
| Personality Inventory | 1 | 1990 | 130 | 0.080 |
Why?
|
| Factor Analysis, Statistical | 1 | 2010 | 257 | 0.080 |
Why?
|
| Observer Variation | 1 | 2010 | 298 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 1257 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2018 | 4595 | 0.080 |
Why?
|
| Animals | 9 | 2018 | 31565 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2014 | 459 | 0.080 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 158 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 666 | 0.080 |
Why?
|
| Pregnancy in Diabetics | 1 | 1990 | 82 | 0.080 |
Why?
|
| Apoptosis | 6 | 2012 | 2349 | 0.080 |
Why?
|
| Adolescent | 12 | 2019 | 17800 | 0.080 |
Why?
|
| Risk | 5 | 2013 | 810 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1726 | 0.080 |
Why?
|
| Exercise Therapy | 1 | 2012 | 351 | 0.080 |
Why?
|
| Single-Blind Method | 2 | 2024 | 259 | 0.080 |
Why?
|
| Glycemic Index | 1 | 2008 | 20 | 0.080 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2008 | 9 | 0.080 |
Why?
|
| Cell Cycle | 3 | 2006 | 541 | 0.080 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 75 | 0.080 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2008 | 48 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 340 | 0.080 |
Why?
|
| Young Adult | 5 | 2017 | 10444 | 0.080 |
Why?
|
| Cluster Analysis | 2 | 2006 | 452 | 0.070 |
Why?
|
| Fluorouracil | 1 | 2008 | 152 | 0.070 |
Why?
|
| Receptors, Calcitriol | 1 | 2008 | 53 | 0.070 |
Why?
|
| Inflammation | 1 | 2018 | 2464 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2012 | 493 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2008 | 138 | 0.070 |
Why?
|
| Prevalence | 4 | 2018 | 2247 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 1131 | 0.070 |
Why?
|
| Receptors, Vitronectin | 1 | 2007 | 8 | 0.070 |
Why?
|
| GTP-Binding Proteins | 2 | 2019 | 139 | 0.070 |
Why?
|
| Transglutaminases | 2 | 2019 | 142 | 0.070 |
Why?
|
| Snake Venoms | 1 | 2007 | 18 | 0.070 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2007 | 20 | 0.070 |
Why?
|
| Age of Onset | 3 | 2017 | 444 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 1990 | 330 | 0.070 |
Why?
|
| Integrins | 1 | 2007 | 80 | 0.070 |
Why?
|
| Health Behavior | 1 | 2012 | 701 | 0.070 |
Why?
|
| Killer Cells, Natural | 1 | 2009 | 380 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 445 | 0.070 |
Why?
|
| Interleukin-2 | 3 | 2006 | 413 | 0.070 |
Why?
|
| Cross-Sectional Studies | 4 | 2019 | 4402 | 0.070 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 1690 | 0.070 |
Why?
|
| Signal Transduction | 4 | 2012 | 4501 | 0.070 |
Why?
|
| Gene Expression | 3 | 2007 | 1417 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2006 | 74 | 0.070 |
Why?
|
| Infant, Newborn | 5 | 2012 | 5038 | 0.070 |
Why?
|
| Registries | 3 | 2019 | 1764 | 0.070 |
Why?
|
| Liver Neoplasms | 2 | 2012 | 504 | 0.070 |
Why?
|
| Coronary Disease | 1 | 1988 | 348 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 924 | 0.060 |
Why?
|
| Maternal Age | 1 | 2006 | 116 | 0.060 |
Why?
|
| Body Mass Index | 1 | 2013 | 1957 | 0.060 |
Why?
|
| Multigene Family | 1 | 2006 | 190 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2007 | 213 | 0.060 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2006 | 66 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 499 | 0.060 |
Why?
|
| ROC Curve | 2 | 2021 | 441 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2008 | 444 | 0.060 |
Why?
|
| Parents | 1 | 2013 | 1181 | 0.060 |
Why?
|
| Radiotherapy, Conformal | 1 | 2005 | 68 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 610 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2019 | 286 | 0.060 |
Why?
|
| Life Style | 2 | 2020 | 428 | 0.060 |
Why?
|
| Herpes Genitalis | 1 | 2004 | 16 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 496 | 0.060 |
Why?
|
| Neoplasms | 2 | 2008 | 2086 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 192 | 0.060 |
Why?
|
| Herpesvirus 2, Human | 1 | 2004 | 27 | 0.060 |
Why?
|
| Social Workers | 1 | 2024 | 32 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2004 | 120 | 0.060 |
Why?
|
| Epithelium | 2 | 2018 | 295 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2007 | 427 | 0.050 |
Why?
|
| Gestational Age | 1 | 2006 | 761 | 0.050 |
Why?
|
| Genetic Linkage | 1 | 2003 | 294 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2004 | 256 | 0.050 |
Why?
|
| Proteome | 1 | 2006 | 337 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 1228 | 0.050 |
Why?
|
| Linear Models | 2 | 2018 | 768 | 0.050 |
Why?
|
| Nurse's Role | 1 | 2024 | 103 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 438 | 0.050 |
Why?
|
| Ligases | 1 | 2002 | 30 | 0.050 |
Why?
|
| Bradykinin | 1 | 2002 | 41 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2008 | 533 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2017 | 336 | 0.050 |
Why?
|
| DNA Copy Number Variations | 2 | 2013 | 153 | 0.050 |
Why?
|
| Nurses | 1 | 2024 | 145 | 0.050 |
Why?
|
| Counseling | 1 | 2004 | 342 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2008 | 913 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2002 | 139 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2006 | 868 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2002 | 190 | 0.050 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2002 | 91 | 0.040 |
Why?
|
| Trauma Severity Indices | 2 | 2018 | 108 | 0.040 |
Why?
|
| Terminal Care | 1 | 2024 | 212 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2002 | 164 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2008 | 742 | 0.040 |
Why?
|
| Vaccines, DNA | 1 | 2000 | 29 | 0.040 |
Why?
|
| Angina Pectoris | 1 | 2020 | 63 | 0.040 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2000 | 45 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2024 | 479 | 0.040 |
Why?
|
| Disability Evaluation | 2 | 2012 | 271 | 0.040 |
Why?
|
| Sodium Bicarbonate | 1 | 2020 | 40 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 2020 | 78 | 0.040 |
Why?
|
| Fetal Blood | 1 | 2002 | 268 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2002 | 283 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2006 | 650 | 0.040 |
Why?
|
| Propensity Score | 1 | 2020 | 225 | 0.040 |
Why?
|
| Retinal Vessels | 1 | 1999 | 50 | 0.040 |
Why?
|
| Acetylcysteine | 1 | 2020 | 141 | 0.040 |
Why?
|
| Optic Disk | 1 | 1999 | 38 | 0.040 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2019 | 61 | 0.040 |
Why?
|
| Papilledema | 1 | 1999 | 40 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2000 | 232 | 0.040 |
Why?
|
| Work Capacity Evaluation | 1 | 2018 | 11 | 0.040 |
Why?
|
| Diet Surveys | 1 | 2019 | 78 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2019 | 164 | 0.040 |
Why?
|
| gamma Catenin | 1 | 2018 | 17 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2004 | 663 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2000 | 256 | 0.040 |
Why?
|
| Desmoglein 3 | 1 | 2018 | 17 | 0.040 |
Why?
|
| Metaplasia | 1 | 2018 | 54 | 0.040 |
Why?
|
| Bronchial Diseases | 1 | 2018 | 35 | 0.040 |
Why?
|
| Limb Salvage | 1 | 2018 | 51 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2018 | 84 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2020 | 225 | 0.040 |
Why?
|
| Time | 1 | 2018 | 70 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 1624 | 0.040 |
Why?
|
| Thermodilution | 1 | 2017 | 12 | 0.040 |
Why?
|
| Tennessee | 1 | 2017 | 38 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2012 | 2550 | 0.040 |
Why?
|
| Proteins | 1 | 2003 | 906 | 0.040 |
Why?
|
| Workload | 1 | 2018 | 131 | 0.040 |
Why?
|
| SEER Program | 2 | 2014 | 195 | 0.040 |
Why?
|
| Cytokines | 1 | 2005 | 1824 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 1735 | 0.040 |
Why?
|
| Smokers | 1 | 2018 | 129 | 0.040 |
Why?
|
| Industry | 1 | 2017 | 65 | 0.030 |
Why?
|
| HLA-DR4 Antigen | 1 | 2017 | 76 | 0.030 |
Why?
|
| HLA-DR3 Antigen | 1 | 2017 | 79 | 0.030 |
Why?
|
| Age Distribution | 1 | 2017 | 341 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 2 | 2008 | 183 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 925 | 0.030 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 192 | 0.030 |
Why?
|
| Machine Learning | 1 | 2020 | 315 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2002 | 1016 | 0.030 |
Why?
|
| Centrosome | 1 | 2016 | 59 | 0.030 |
Why?
|
| Workplace | 1 | 2017 | 221 | 0.030 |
Why?
|
| Community Health Centers | 1 | 1996 | 53 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 373 | 0.030 |
Why?
|
| Cisplatin | 2 | 2007 | 262 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2020 | 632 | 0.030 |
Why?
|
| Dacarbazine | 2 | 2006 | 99 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 102 | 0.030 |
Why?
|
| Anxiety Disorders | 2 | 2006 | 304 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2018 | 333 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2012 | 636 | 0.030 |
Why?
|
| Occupational Exposure | 1 | 2018 | 255 | 0.030 |
Why?
|
| Sample Size | 1 | 2015 | 109 | 0.030 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 2 | 2006 | 23 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2007 | 119 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2015 | 156 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 549 | 0.030 |
Why?
|
| Marital Status | 1 | 2014 | 41 | 0.030 |
Why?
|
| Dabigatran | 1 | 2014 | 22 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2017 | 329 | 0.030 |
Why?
|
| Seat Belts | 1 | 1994 | 18 | 0.030 |
Why?
|
| Endoscopy | 1 | 2015 | 245 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2017 | 1015 | 0.030 |
Why?
|
| HLA-DR2 Antigen | 1 | 2012 | 8 | 0.030 |
Why?
|
| Protective Clothing | 1 | 2012 | 17 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 48 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 1994 | 169 | 0.030 |
Why?
|
| HLA-DQ beta-Chains | 1 | 2012 | 57 | 0.030 |
Why?
|
| Placebos | 1 | 2012 | 197 | 0.030 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2012 | 43 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2012 | 87 | 0.030 |
Why?
|
| HLA-DRB1 Chains | 1 | 2012 | 97 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 151 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2014 | 250 | 0.020 |
Why?
|
| Transcription Factors | 3 | 2006 | 1526 | 0.020 |
Why?
|
| Research Design | 1 | 2017 | 919 | 0.020 |
Why?
|
| Skin Pigmentation | 1 | 2012 | 39 | 0.020 |
Why?
|
| Genes, ras | 1 | 2012 | 91 | 0.020 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2011 | 7 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2014 | 246 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 1218 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 489 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 301 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 979 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 307 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 1331 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2011 | 37 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 182 | 0.020 |
Why?
|
| HIV Infections | 1 | 2004 | 2453 | 0.020 |
Why?
|
| Language | 1 | 2013 | 263 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 725 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 802 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 384 | 0.020 |
Why?
|
| Face | 1 | 2012 | 163 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2013 | 477 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2011 | 160 | 0.020 |
Why?
|
| Cell Division | 2 | 2002 | 754 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2014 | 325 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 431 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 695 | 0.020 |
Why?
|
| Postural Balance | 1 | 2012 | 185 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 534 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 1143 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 1052 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2017 | 898 | 0.020 |
Why?
|
| Smad3 Protein | 1 | 2009 | 41 | 0.020 |
Why?
|
| Body Composition | 1 | 2013 | 590 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 273 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2009 | 64 | 0.020 |
Why?
|
| Glucose Tolerance Test | 1 | 1990 | 343 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 227 | 0.020 |
Why?
|
| Celecoxib | 1 | 2008 | 38 | 0.020 |
Why?
|
| Capecitabine | 1 | 2008 | 45 | 0.020 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2008 | 11 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2009 | 312 | 0.020 |
Why?
|
| Pigmentation | 1 | 2009 | 54 | 0.020 |
Why?
|
| Mesoderm | 1 | 2009 | 138 | 0.020 |
Why?
|
| Health Surveys | 1 | 1990 | 441 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1988 | 115 | 0.020 |
Why?
|
| Polycomb-Group Proteins | 1 | 2008 | 29 | 0.020 |
Why?
|
| Walking | 1 | 2012 | 422 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2008 | 57 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 80 | 0.020 |
Why?
|
| Bronchoscopy | 1 | 2009 | 196 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2008 | 42 | 0.020 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2008 | 38 | 0.020 |
Why?
|
| Software | 1 | 2012 | 526 | 0.020 |
Why?
|
| Regression Analysis | 1 | 1990 | 945 | 0.020 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2008 | 62 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 863 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2011 | 459 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2009 | 552 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 1988 | 150 | 0.020 |
Why?
|
| Family Health | 1 | 2008 | 193 | 0.020 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2007 | 45 | 0.020 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2008 | 96 | 0.020 |
Why?
|
| Genome, Human | 1 | 2009 | 347 | 0.020 |
Why?
|
| Carbon Monoxide | 1 | 1987 | 64 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2008 | 243 | 0.020 |
Why?
|
| Psychometrics | 1 | 1990 | 608 | 0.020 |
Why?
|
| Infant, Low Birth Weight | 1 | 1987 | 124 | 0.020 |
Why?
|
| Health Promotion | 1 | 2012 | 675 | 0.020 |
Why?
|
| Diabetic Angiopathies | 1 | 2008 | 246 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2007 | 167 | 0.020 |
Why?
|
| Vinblastine | 1 | 2006 | 63 | 0.020 |
Why?
|
| Calcinosis | 1 | 2008 | 239 | 0.020 |
Why?
|
| Mice, Inbred A | 1 | 2005 | 45 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2005 | 31 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 1176 | 0.020 |
Why?
|
| Energy Intake | 1 | 2008 | 427 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2006 | 140 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 385 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2008 | 367 | 0.020 |
Why?
|
| Enzymes | 1 | 2005 | 62 | 0.020 |
Why?
|
| Antiemetics | 1 | 2005 | 32 | 0.020 |
Why?
|
| Melphalan | 1 | 2005 | 29 | 0.020 |
Why?
|
| Carcinogens | 1 | 2005 | 102 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2006 | 373 | 0.020 |
Why?
|
| Interferon-alpha | 1 | 2006 | 185 | 0.020 |
Why?
|
| Eye Neoplasms | 1 | 2005 | 14 | 0.020 |
Why?
|
| Mood Disorders | 1 | 2006 | 112 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2005 | 117 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 1880 | 0.010 |
Why?
|
| Carboplatin | 1 | 2005 | 135 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 1117 | 0.010 |
Why?
|
| Trichomonas Infections | 1 | 2004 | 7 | 0.010 |
Why?
|
| Vaginosis, Bacterial | 1 | 2004 | 11 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2005 | 68 | 0.010 |
Why?
|
| Genomics | 1 | 2009 | 631 | 0.010 |
Why?
|
| Heart | 1 | 1988 | 613 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 541 | 0.010 |
Why?
|
| DNA Replication | 1 | 2005 | 202 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2006 | 305 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 140 | 0.010 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2006 | 197 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2004 | 256 | 0.010 |
Why?
|
| Air Pollutants | 1 | 1987 | 244 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 2004 | 137 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2003 | 16 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 591 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2003 | 22 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2003 | 30 | 0.010 |
Why?
|
| Adult Children | 1 | 2003 | 21 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2003 | 56 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2003 | 66 | 0.010 |
Why?
|
| Transfection | 1 | 2006 | 863 | 0.010 |
Why?
|
| Condoms | 1 | 2004 | 112 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2003 | 60 | 0.010 |
Why?
|
| Lithium | 1 | 2003 | 36 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 181 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2003 | 77 | 0.010 |
Why?
|
| Fetus | 1 | 1987 | 698 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2005 | 344 | 0.010 |
Why?
|
| Pedigree | 1 | 2003 | 460 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2003 | 486 | 0.010 |
Why?
|
| Risk Reduction Behavior | 1 | 2004 | 200 | 0.010 |
Why?
|
| COP9 Signalosome Complex | 1 | 2002 | 6 | 0.010 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2002 | 11 | 0.010 |
Why?
|
| Gastrointestinal Tract | 1 | 2004 | 169 | 0.010 |
Why?
|
| Wnt Proteins | 1 | 2003 | 134 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2007 | 677 | 0.010 |
Why?
|
| Tetrazolium Salts | 1 | 2002 | 18 | 0.010 |
Why?
|
| Rats, Nude | 1 | 2002 | 26 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2004 | 274 | 0.010 |
Why?
|
| Wings, Animal | 1 | 2002 | 32 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2002 | 140 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 77 | 0.010 |
Why?
|
| COS Cells | 1 | 2002 | 175 | 0.010 |
Why?
|
| Histone Deacetylases | 1 | 2003 | 194 | 0.010 |
Why?
|
| Mediastinal Neoplasms | 1 | 2002 | 32 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2002 | 88 | 0.010 |
Why?
|
| Dimerization | 1 | 2002 | 176 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 145 | 0.010 |
Why?
|
| Thiazoles | 1 | 2002 | 110 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 2002 | 103 | 0.010 |
Why?
|
| Pregnancy | 2 | 1990 | 5499 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2002 | 292 | 0.010 |
Why?
|
| Drosophila | 1 | 2002 | 133 | 0.010 |
Why?
|
| Health Status | 1 | 2006 | 716 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 269 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2005 | 873 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2008 | 1072 | 0.010 |
Why?
|
| Superantigens | 1 | 2000 | 69 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 350 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 771 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2002 | 136 | 0.010 |
Why?
|
| Endoplasmic Reticulum | 1 | 2002 | 234 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2002 | 168 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2002 | 714 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 796 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2002 | 388 | 0.010 |
Why?
|
| Graft Survival | 1 | 2002 | 443 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2002 | 341 | 0.010 |
Why?
|
| Alcoholism | 1 | 2006 | 710 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2000 | 286 | 0.010 |
Why?
|
| Plasmids | 1 | 2000 | 343 | 0.010 |
Why?
|
| HIV-1 | 1 | 2004 | 768 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 133 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2002 | 735 | 0.010 |
Why?
|
| Kidney | 1 | 2005 | 1182 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 324 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2006 | 942 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 1633 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 1310 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 2783 | 0.010 |
Why?
|
| Neutrophils | 1 | 2002 | 1089 | 0.010 |
Why?
|
| Cell Line | 1 | 2002 | 2629 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2005 | 3498 | 0.010 |
Why?
|
| Calcium | 1 | 2002 | 1089 | 0.010 |
Why?
|
| Aging | 1 | 2006 | 1611 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 1311 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 1994 | 33 | 0.010 |
Why?
|
| Rats | 1 | 2002 | 4913 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1994 | 167 | 0.010 |
Why?
|
| Urban Population | 1 | 1996 | 396 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 1996 | 1080 | 0.010 |
Why?
|
| Health Care Costs | 1 | 1994 | 381 | 0.010 |
Why?
|